A New Method for Monitoring Antibody Internalization in Cancer Cells
Author Information
Author(s): Ulrik B. Nielsen, Dmitri B. Kirpotin, Edward M. Pickering, Daryl C. Drummond, James D. Marks
Primary Institution: University of California San Francisco
Hypothesis
Can a novel assay effectively monitor the internalization of antibody-conjugated liposomes in tumor cells?
Conclusion
The CLIA method is a rapid and sensitive assay for identifying tumor-specific antibodies that can efficiently deliver drugs when conjugated to liposomal carriers.
Supporting Evidence
- The CLIA method allows for high throughput screening of antibodies for internalization capabilities.
- Internalization was shown to correlate with receptor expression levels in tumor cell lines.
- The assay requires only small amounts of antibody and can utilize unpurified samples.
Takeaway
Scientists created a new test to see how well certain antibodies can get inside cancer cells to deliver medicine. This test helps find the best antibodies for treating tumors.
Methodology
The study developed the Chelated Ligand Internalization Assay (CLIA) to measure the internalization of histidine-tagged antibodies conjugated to Ni-NTA liposomes in tumor cells.
Limitations
The assay may not be generalizable to all types of antibodies or ligands due to variations in size and valency affecting internalization efficiency.
Statistical Information
P-Value
p<0.03
Statistical Significance
p<0.03
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website